Relapsed/refractory autoimmune diseases
Clinical trials for Relapsed/refractory autoimmune diseases explained in plain language.
Never miss a new study
Get alerted when new Relapsed/refractory autoimmune diseases trials appear
Sign up with your email to follow new studies for Relapsed/refractory autoimmune diseases, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental CAR t therapy takes on autoimmune diseases
Disease control Recruiting nowThis early-stage trial tests a new treatment called AFN50 for people with autoimmune diseases that haven't responded to standard therapies. AFN50 is a type of CAR T-cell therapy designed to target and destroy faulty immune cells. The study will enroll 18 adults to check if the tr…
Matched conditions: RELAPSED/REFRACTORY AUTOIMMUNE DISEASES
Early phase 1 • Sponsor: Beijing Boren Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Engineered immune cells take on autoimmune diseases in early trial
Disease control Recruiting nowThis early-phase study is testing a new cell therapy called LUCAR-DKS1 in 36 adults with relapsed or refractory autoimmune diseases like lupus. Participants receive their own modified NK cells after a short chemotherapy prep. The main goals are to check safety, find the right dos…
Matched conditions: RELAPSED/REFRACTORY AUTOIMMUNE DISEASES
Early phase 1 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Immune reset: CAR-T therapy takes on autoimmune diseases
Disease control Recruiting nowThis early-stage trial tests a treatment called CAR-T cell therapy for people with severe autoimmune diseases that haven't responded to other treatments. The therapy uses a patient's own immune cells, modified to target and reset the immune system. Only 3 participants will be enr…
Matched conditions: RELAPSED/REFRACTORY AUTOIMMUNE DISEASES
Sponsor: ShenZhen Cell Valley • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC